Position in MEDP
as of Jun 30, 2026
· filed Jul 30, 2026
Position Value
$238,315
+$22,230 QoQ
Shares Held
450
0.0% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#514
of 689 holders
Holding Since
Mar 2023
11 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in MEDP Over Time
Shares Held
Position Value (USD)
Position in Diagnostics & Research
Healthcare · as of Jun 30, 2026BAILARD, INC. holds $20,421,713 across 9 Diagnostics & Research names. MEDP ranks #8 (1.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | DHR |
Danaher Corp /De/
|
66,702 | $12,705,396 | |
| 2 | TMO |
Thermo Fisher Scientific Inc.
|
6,041 | $3,028,715 | |
| 3 | IDXX |
Idexx Laboratories Inc /De
|
3,995 | $2,103,127 | |
| 4 | DGX |
Quest Diagnostics Inc
|
5,681 | $1,204,087 | |
| 5 | MTD |
Mettler Toledo International Inc/
|
303 | $387,085 | |
| 6 | A |
Agilent Technologies, Inc.
|
2,275 | $302,188 | |
| 7 | CDNA |
CareDx, Inc.
|
8,700 | $247,950 | |
| 8 | MEDP |
Medpace Holdings, Inc.
This page
|
450 | $238,315 |
All Filings in MEDP
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $238,315 | 450 | Shares | Sole | 2026-07-30 | |
| 2026-03-31 | $216,085 | 450 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $252,742 | 450 | Shares | Sole | 2026-02-04 | |
| 2025-09-30 | $231,372 | 450 | Shares | Sole | 2025-10-30 | |
| 2024-09-30 | $250,350 | 750 | Shares | Sole | 2024-10-30 | |
| 2024-06-30 | $308,887 | 750 | Shares | Sole | 2024-07-25 | |
| 2024-03-31 | $303,112 | 750 | Shares | Sole | 2024-05-08 | |
| 2023-12-31 | $229,897 | 750 | Shares | Sole | 2024-02-02 | |
| 2023-09-30 | $278,449 | 1,150 | Shares | Sole | 2023-10-24 | |
| 2023-06-30 | $276,195 | 1,150 | Shares | Sole | 2023-07-20 | |
| 2023-03-31 | $216,257 | 1,150 | Shares | Sole | 2023-05-08 | |
| No filing history on record for this holder in this stock. | ||||||